Company intelligence / Profile preview
PureTech Health
Boston, Massachusetts, United Statespuretechhealth.com ↗
- Ownership
- Public · PRTC
- Employees
- ~90
- Development stage
- Other
01
Overview
Currently developing multiple clinical-stage programs including LYT-100 in Phase 2 for idiopathic pulmonary fibrosis and LYT-200 in Phase 1/2 for solid tumors and hematological malignancies
- Therapeutic areas
- PulmonologyPsychiatryCardiovascularImmunologyOtherOncologyNeurologyInfectious Diseases
- Modalities
- Monoclonal antibodiesOral drugsHydrogelsPeptide therapeutics
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on PureTech Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PureTech Health.